GreenLight Biosciences, Samsung Biologics Collaborate to Advance COVID-19 Vaccine Candidate

Published on: 

Samsung Biologics will manufacture GreenLight BioSciences' COVID-19 vaccine candidate for clinical trials and commercial sales.

GreenLight Biosciences, a biotechnology company, and Samsung Biologics, a global contract development and manufacturing organization (CDMO), have partnered up to advance GreenLight’s messenger RNA (mRNA) COVID-19 vaccine candidate, it was announced in a Nov. 25, 2021 press release.

Under the terms of the partnership, Samsung will manufacture GreenLight’s vaccine candidate for Phase III clinical trials and commercial sales (subject to regulatory approval). GreenLight’s existing manufacturing process will be leveraged by Samsung, with technology transfer between the companies already underway.

“We are delighted to partner with Samsung to manufacture messenger RNA for our COVID vaccine trial. There is an urgent need to develop vaccines for the whole world,” said GreenLight CEO Andrey Zarur, in the press release. “Our vaccine trial will open the way to make vaccines that are available to everybody, not just citizens of developed countries.”


“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA COVID-19 vaccine candidate to better serve patients in lower income countries,” added John Rim, CEO of Samsung Biologics, in the press release. “This collaboration demonstrates a major milestone for Samsung Biologics as we will commence our expanded capabilities and operations to provide one-stop end-to-end messenger RNA production from drug substance to aseptic fill/finish to commercial release, all from a single site. At this time of urgent global demand, we will strive for seamless service across our biomanufacturing network to fight the COVID pandemic and in turn, help make progress towards Korea's vaccine hub goal.”

Source: Samsung Biologics